The effect of tobacco smoking and treatment strategy on the one-year mortality of patients with acute non-ST-segment elevation myocardial infarction

Table 1 Baseline characteristics for NSTEMI patients.

	Non-smokers			Smokers*
	CS (n = 127)	IS (n = 151)	p-value	CS (n = 54)	IS (n = 49)	p-value
Age (years)	79 (72-86)	81 (69-86)	0.61	66 (56-76)	60 (55-72)	0.17
Male	74 (58%)	87 (58%)	1.00	39 (72%)	34 (69%)	0.92
Medical history
Diabetes	21 (17%)	29 (19%)	0.67	6 (11%)	6 (12%)	1.00
Previous AMI	42 (33%)	53 (35%)	0.82	14 (26%)	12 (25%)	1.00
Previous LVSD†	10 (8%)	19 (13%)	0.30	7 (13%)	3 (6%)	0.40
Hypertension	46 (36%)	45 (30%)	0.31	17 (32%)	13 (27%)	0.74
Stroke	6 (5%)	17 (11%)	0.080	6 (11%)	2 (4%)	0.34
CABG	11 (9%)	20 (13%)	0.31	5 (9%)	3 (6%)	0.82
PCI	6 (5%)	10 (7%)	0.68	3 (6%)	10 (20%)	0.049
Presenting characteristics
S-Creatinine, μmol/L‡	95 (76-128)	90 (77-115)	0.30	95 (75-116)	76 (69-97)	0.014
GRACE risk score	140 (113-166)	139 (110-164)	0.53	112 (84-160)	108 (80-131)	0.28

Categorical data presented as n (%) and continuous data as median (25^th -75^th percentile). *Smoking within last three months. †Defined as prior left ventricular ejection fraction < 40%. ‡Conversion factor 0.0113 for mg/dL.
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CS, conservative strategy cohort; GRACE, global registry of acute coronary events; IS, invasive strategy cohort; LVSD, left ventricular systolic dysfunction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

ISSN: 1471-2261